Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Program for PCNAT-01, a Personalized Tumor Neoantigen Peptide Vaccine, in Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Completion of Adjuvant Chemotherapy

NCT07612930 is registered in ClinicalTrials.gov with Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. as lead sponsor.

NCT NCT07612930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Program for PCNAT-01, a Personalized Tumor Neoantigen Peptide Vaccine, in Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Completion of Adjuvant Chemotherapy
Lead sponsor
Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac)